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Central venous catheter (CVC) as hemodialysis (HD) access
is associated with great morbidity and mortality in the
end-stage renal disease population. Quotidian, nocturnal
HD (NHD) is a novel dialysis modality associated with
cardiovascular and quality of life benefits, yet there is a
concern of a potential increase in vascular access-related
complications through patient-directed access cannulation.
We aimed to determine catheter incidence and prevalence
in the NHD population and to compare rates of
catheter-related: infection, thrombolytic administration,
hospitalization, survival, and reasons for their loss before and
after conversion to NHD. This observational cohort consisted
of incident and prevalent NHD patients between 1 November
1993 and 31 May 2005. Rate comparisons were determined
by Poisson analysis and catheter survival by Kaplan–Meier
curves. Eighty-one CVCs in 33 patients accounted for 17 150
CVC days (CVCD); 40 CVCs were exclusively used for
conventional three times weekly HD (CHD) and 25 CVCs were
exclusively used during NHD. The incidence and prevalence
of CVC use in our NHD population was 35 and 25%,
respectively. Comparing CHD to NHD, no significant
differences were seen in total rates of infection, thrombolytic
administration, or access-related hospitalization. Catheter
survival was superior in NHD vs CHD (P¼ 0.03). Adverse
terminal catheter events were higher during CHD than NHD
(5.84 vs 2.92/1000 CVCD; P¼ 0.03). CVC use and
complications in NHD is comparable to that in CHD with the
benefit of longer cumulative survival. More frequent CVC use
should not be a deterrent to NHD.
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The central venous catheter (CVC) is the hemodialysis (HD)
patient’s double-edged sword. When a permanent access is
not possible, it provides the only option for vascular access,
yet it is associated with the greatest access-related morbidity
and mortality1–6 of all access types. CVCs are associated with
the highest rates of infection and septicemia, lower dialysis
dose delivery per time on HD, and increased rates of central
venous stenosis,7–10 further precluding the establishment of
permanent vascular access. Lastly, higher rates of CVC
complications may also interrupt or shorten treatments and
may lead to increased hospital admissions.
In 1994, when quotidian, nocturnal HD (NHD) was
introduced as a novel form of renal replacement therapy,11 it
was the Uldall–Cook CVC (Uldall–Cook catheter, Cook
Critical Care, Bloomington, IN, USA) developed by the very
same group that provided reliable vascular access.12 Dr Uldall
and his group preferred the CVC for vascular access in NHD
patients, as it was felt to provide the securest connection to
the patient’s circulation, thereby minimizing the risk of
accidental disconnection from the dialysis line.
Although there has been abundant growth in quotidian
NHD technology and research, the effect of intensive nightly,
patient-directed HD on vascular access complications has,
until recently, remained largely unknown. The possibility of
increased vascular access complications owing to nightly
access cannulation at twice the frequency of CHD may be a
factor limiting the widespread use of NHD. To date, there are
few studies describing the incidence, prevalence, and out-
comes of CVC use in the NHD patient population.
Here, we report the incidence and prevalence of CVC use
in the NHD population. We hypothesize that the complica-
tions and cumulative patency of CVC used for NHD are
comparable to those used for CHD in our dialysis programs
at the University Health Network – Toronto General Hospital
(UHN–TGH).
RESULTS
During the study period, 59 patients were enrolled in the
NHD program as of May 2005. One patient received a renal
transplant in May 2005 and was therefore excluded. No
patients died. Fifty-seven percent (n¼ 33) of patients have
been maintained on a CVC as their dialysis access at some
point during HD and were included in the analysis. Patient
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characteristics are shown in Table 1 and are compared to
those patients who have been maintained solely on a
surgically created permanent vascular access. The median
age is 39 years with 39.4% men and 78.8% Caucasian. Twelve
percent of patients have only ever been on NHD as their renal
replacement therapy and the median duration of NHD was
44.4 months. Comparing the study cohort to patients
maintained solely with a permanent vascular access, study
patients were more likely to be female (60.6%, P¼ 0.003),
and have been on a previous form of renal replacement
therapy other than NHD (87.9%, P¼ 0.03). There was a
trend towards increased diabetes (24.3%) and malignancy
history (15.2%) in the study group.
A total of 81 CVCs were inserted into 33 patients from
November 1993 to May 2005. CVC characteristics by their
period of use are provided in Table 2. Forty CVCs were used
exclusively for CHD in 17 patients, 25 CVCs were used in 12
patients during NHD, and 16 CVCs were used in 16 patients
during NHD training. Regarding its use for NHD, 35%
(n¼ 20) initiated NHD with a CVC, whereas the prevalent
rate of CVC use was 26% (n¼ 15). Of the total number of
CVCs, 34 (42%) CVCs were the first CVC used by a patient,
17 (21%) were the first and only CVC used, 16 (20%) were
the second CVC, nine (11%) were the third CVC, eight
(10%) were the fourth CVC, and 14 (17%) were the fifth or
greater CVC used by a patient (see Table 2 for comparison
with CHD and NHD training).
Rates of all CVC complications studied during CHD and
NHD are provided in Table 3. In the comparison of CVC
used for CHD vs NHD, no differences were found in total
rates of infection (1.73 vs 2.29 events/1000 CVC days
(CVCD), P¼ 0.55). Moreover, rates of true catheter-related
bacteremia comprised the bulk of infections in both the CHD
and NHD catheters at 1.08 and 1.88 infections/1000 CVCD,
respectively, but were not different between the groups
(P¼ 0.33). Exit site/tunnel infections in the CHD catheters
compared to NHD catheters were 0.43 vs 0.21 infections/
1000 CVCD (P¼ 0.26).
No differences in recombinant tissue plasminogen acti-
vator (r-TPA) administration were seen between CHD and
NHD catheters (4.32 vs 4.38 events/1000 CVCD, P¼ 0.97).
Similarly, access-related hospitalization did not differ
between the two groups (Table 3).
Adverse terminal event rates differed significantly between
CHD and NHD catheters. Total adverse terminal loss was
5.84 events/1000 CVCD and 2.92 events/1000 CVCD in the
CHD and NHD groups, respectively (P¼ 0.03). The majority
of catheters in the CHD group were lost owing to poor flow
Table 1 | Prevalent NHD patient characteristics based on
vascular access type
Variable
Study population
(CVC use)
Permanent vascular
access
N 33 25
Age at start of NHD
Mean/median (range) 40/39 (24–60) 43.5/40.2 (22-65)
NHD as sole RRT modalitya 4 (12%) 10 (40%)
Gender (male) 13 (39%) 20 (80%)
Ethnicityb
Caucasian 26 (79%) 20 (80%)
Southeast Asian 2 (6%) 1 (4%)
South Asian 2 (6%) 3 (12%)
Black 3 (9%) 1 (4%)
Duration of NHD (months)
Mean/median (range) 66.5/44.4 (5–198) 71/65.3 (4–199)
Etiology of ESRD
(i) GN 12 (36%) 9 (36%)
(ii) DM 7 (21%) 1 (4%)
(iii) HTN 0 (0%) 2 (8%)
(iv) PCKD 3 (9%) 6 (24%)
(v) Other congenital 2 (6%) 3 (12%)
(vi) Other 9 (27%) 2 (8%)
(vii) Unknown 0 (0%) 2 (8%)
Comorbiditiesc
DM 8 (24.3%) 3 (12%)
CVA/TIA 3 (9%) 2 (8%)
PVD 1 (3%) 0 (0%)
CAD 3 (9%) 1 (4%)
Dyslipidemia 6 (18%) 2 (8%)
CHF 2 (6%) 0 (0%)
HTEN 23 (70%) 13 (52%)
History of malignancy 5 (15%) 1 (4%)
CAD, coronary artery disease; CHF, congestive heart failure; CVA/TIA, cereberovas-
culan accident/transient ischemic attach; CVC, central venous catheter; DM,
diabetes; ESRD, end-stage renal disease; GN, glomerulonephritis; HTN, hypertension;
NHD, nocturnal hemodialysis; PCKD, polycystic kidney disease; PVD, peripheral
vascular disease; RRT, renal replacement theory.
aThose individuals who have only been exposed to NHD and have never had a renal
transplant or any other prior forms of RRT.
bCaucasian (white); Oriental: Southeast Asian (including patients of Chinese,
Japanese, Korean, and Indo-Chinese origins); South Asian (including patients of
East Indian, Pakistani, and Punjabi origins); black (including black patients from
Africa and Carribean).
cCAD was defined if a patient had a myocardial infarction, or required
revascularization by an angioplasty, stenting, or bypass surgery. PVD was defined
by revascularization, amputation, and/or a history of claudication that also required
having ischemic extremity changes or gangrene. DM was defined if a patient
required the current or prior use of oral hypoglycemic agents or insulin, or had the
diagnosis noted in their medical records at least twice by two different physicians.
Table 2 | Catheter characteristics by period of use
CVC characteristics NHD (n=25) CHD (n=40) Training (n=16)
CVCD
Total 4795 4627 7728
Mean/median 127/191 118/66 483/345
Range 1–693 1–571 69–2149
CVC 1-year survival 4 (16%) 2 (5%) 8 (50%)
R/L IJVa 22 (88%) 38 (95%) 16 (100%)
R/L SCLVa 2 (8%) 1 (2.5%) 0 (0%)
R/L FVa 1 (4%) 1 (2.5%) 0 (0%)
First and only CVC 2 (8%) 8 (20%) 7 (44%)
First CVC 3 (12%) 18 (45%) 12 (75%)
Subsequent CVC 22 (88%) 22 (55%) 4 (25%)
CHD, conventional hemodialysis; CVC, central venous catheter; NHD, nocturnal
hemodialysis; R/L IJV, right/left internal jugular vein; R/L FV, right/left femoral vein;
R/L SCLV, right/left subclavian vein.
aDenotes location of catheter.
Kidney International (2006) 70, 1348–1354 1349
J Perl et al.: Central venous catheter outcomes o r i g i n a l a r t i c l e
(4.32 events/1000 CVCD) compared to the NHD group (0.42
events/1000 CVCD) (Po0.0001). Comparing NHD CVC vs
CHD CVC, infection was the leading cause of catheter loss in
the NHD group (1.67 events/1000 CVCD) compared to 0.65
events/1000 CVCD in the CHD group (P¼ 0.16). Non-
terminal complications were similar between the CHD and
NHD groups.
Catheter survival for the CVC used during NHD and
CHD is shown in Figure 1. Cumulative catheter survival was
superior in the NHD group (P¼ 0.03) with 191 median days
compared with 66 median days observed in CHD catheters.
DISCUSSION
An incidence and prevalence of CVC use of 35 and 26%,
respectively, was observed in one of the largest NHD cohorts
followed for CVC outcomes. These rates of catheter use are in
keeping with the current Canadian point prevalence rate of
30.9%.13 Compared with recent data from the Dialysis
Outcomes and Practice Patterns study, which demonstrated a
60% incident and 17% prevalent rate of CVC use in the
United States,14 less NHD patients initiate HD with a CVC;
however, there is a higher prevalence of CVC use in the NHD
patients. Our results indicate that patients who have had
NHD as their sole renal replacement modality were less likely
to require the use of a CVC. This may represent a selection
bias, as these patients are often educated and more adherent
to prescribed self-care. These highly motivated patients are
likely to comply with pre-emptive surgical creation of
permanent access. The increased rate of CVC use in women
in the NHD population is in keeping with previous literature,
which has supported the notion that sex is a determinant in
the formation of a surgically created vascular access.15
The prevalence of CVC use is higher in NHD patients than
currently published reports for several reasons. In a subset of
NHD patients, such as those with physical disabilities, and
those with multiple co-morbidities who must resort to NHD
as a salvage therapy after being intolerant of other methods of
renal replacement therapy including CHD, a CVC may be the
only possible option for vascular access. In these patients,
vascular access cannulation is performed by the patient and/
or the patient’s family. A CVC offers a painless method of
cannulation, requiring less patient dexterity and allowing a
secure connection to the patient’s circulation. In this
population, it may reduce the incidence of vascular access
detachment and bleeding but requires more formal study.
Indeed, in a subset of patients, it may be permissible to allow
the use of CVC for chronic maintenance NHD.
Moreover, these data demonstrate that in catheters used
for NHD, rates of infectious complications, thrombolytic
administration, and hospitalization appear to be similar to
catheters used for CHD. Catheters used for NHD have been
demonstrated not only to have less adverse terminal event
rates, but also to improve cumulative survival as compared to
catheters used for CHD.
Although there is experience with vascular access out-
comes in short-daily and home HD,16–21 literature specifically
addressing vascular access outcomes in NHD patients is
limited. Pierratos et al.22,23 has reported encouraging results
with the use of CVC in NHD patients. One-year catheter
survival was reported to be 38% on NHD vs 29% on CHD.
Rates of systemic infection were found to be one infection per
25 patient-months and an exit site infection rate of one per
40 patient-months. In addition, Lockridge et al.24 have also
reported rates of catheter-related bacteremia and exit site
infections of 0.35 and 0.52 events/1000 patient-days,
respectively, with a mean catheter life of 8.5 months in
patients undergoing NHD. Kjellstrand et al.25 found a 1-year
catheter survival of 70%. Lastly, Lindsay et al.26 have similarly
demonstrated no differences in catheter complications
among patients undergoing quotidian/NHD vs daily HD.
Our reported rate of catheter-related bacteremia of 1.88/
1000 CVCD in NHD patients is significantly lower than the
figures of 3.4–6.5 events/1000 CVCD currently reported in
the literature for all HD patients.27–31 Although we found
comparable infection rates between NHD and CHD catheters
in our population, Lindsay et al.26 have demonstrated
Table 3 | CVC complications before and after conversion to
NHD
Event rate/1000 CVCD CHD NHD PCHD:NHD
Infection
Catheter-related bacteremia
(i) True 1.08 1.88 0.33
(ii) Suspected 0.22 0.21 0.98
(iii) Exit/tunnel site (true) 0.43 0.21 0.6
(iv) Total 1.73 2.29 0.55
r-TPA administration 4.32 4.38 0.97
CVC-related hospitalization 0 0.42 0.26
Adverse terminal events
(i) Owing to infection 0.65 1.67 0.16
(ii) Owing to poor flow 4.32 0.42 o0.0001
(iii) Owing to catheter malposition/
cracked hardware
0.65 0.83 0.76
(iv) Unknown 0.22 0 0.49
(v) Total 5.84 2.92 0.03
CHD, coronary heart disease; CVC, central venous catheter; NHD, nocturnal
hemodialysis; r-TPA, recombinant tissue plasminogen activator.
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Figure 1 | Catheter survival in CHD and NHD. Time (weeks from
catheter insertion). Cumulative patency is shown comparing
catheters used for CHD (solid black line) vs those used during
NHD (faint gray line). Cumulative survival was superior in NHD
catheters as compared to CHD catheters (P¼ 0.03).
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reduced catheter-associated infections in patients converted
from CHD to NHD. However, in our cohort, a difference
may not have been detected owing to our already low
infection rates in CHD patients (Munyal et al., J Am Soc
Nephrol 2005; 16: 454A, abstract). There was a trend towards
increased rates of catheter loss due to infection in NHD CVC
over CHD CVC. One particularly likely reason for this trend
is the increased exposure to both intraluminal and extra-
luminal bacterial routes of catheter entry associated with the
greater frequency of catheter manipulation required with
NHD. However, our results suggest that NHD patients’
aseptic technique in catheter manipulation is as effective as
in-center care performed by HD nursing staff. NHD patients
undergo rigorous training where excellent aseptic technique
is emphasized and reinforced. Furthermore, handling of the
catheter by the same trained person eliminates the risk of
cross-contamination that may occur with in-center HD
nurses, who usually oversee and handle multiple catheters
during a dialysis shift.
The bulk of infectious complications during NHD
occurred repeatedly in the same subset of patients, with six
patients being responsible for the 11 total infectious events
and may have benefited from having their technique
reviewed, undergoing further retraining, and being observed
on a more frequent basis. Although hospitalization rates for
catheter-related complications appear to be similar between
groups, what is not known is whether or not a higher
proportion of the total number of hospital admissions in
NHD patients are due to vascular access-related complica-
tions as compared to CHD patients.
Although all groups have found similar, low rates of
complications in catheters used for NHD as compared to
CHD, previous reports show fewer absolute complications
and improved catheter survival in NHD than our findings.
We found that catheter survival at 1 year was 5% for CHD
catheters, and 16% for NHD catheters. Our reduced NHD
catheter survival may be explained by a number of reasons.
Firstly, all catheters including those catheters with primary
failure were included in the analysis. Secondly, we isolated
catheters used exclusively for NHD and excluded those used
in the training period. These catheters were inserted after the
initiation of NHD and were more likely to be second or
subsequent catheters, inserted over a guidewire, which may
be associated with lower survival rates,32 Lastly, catheter-
survival rates vary widely in the literature33–36 so much so
that a reasonable estimate of expected cumulative catheter
patency rates could not be made in the current NKF-DOQI
guidelines.1
Similar rates of thrombolytic administration were seen
between NHD and CHD catheters. However, higher adverse
terminal event rates were seen in CHD with the bulk
comprising terminal events due to poor flow. Although
thrombolytic administration was performed using the same
protocol in both NHD and CHD patients, for NHD patients
r-TPA was more likely to be administrated for 3 consecutive
days when poor flow was suspected (even if catheter flow was
restored after the first treatment). This increased the rate or
r-TPA administration per thrombotic event as compared to
CHD patients who would have received only one dose of
r-TPA (with subsequent doses administered only if persis-
tently poor flows were obtained). Thus, compared to CHD,
rates of r-TPA administration may be greater than rates of
absolute thrombotic episodes in NHD patients.
The decrease in catheter survival in CHD as compared to
NHD may be owing to unique factors specific to NHD that
may make CVC less vulnerable to the ill effects of poor
catheter flow. Firstly, it has been proposed that more frequent
heparinization through nightly exposure may predispose
NHD CVC to less clot and fibrin deposition.23 Secondly,
increased dialysis efficacy may reduce the hypercoagulability
associated with uremia.37,38 Another reason may lie in the
difference as to what constitutes CVC dysfunction in NHD
and CHD CVC. Blood flows (Qb) used in NHD (100–300 ml/
min) are significantly lower than the Qb used routinely for
CHD (400 ml/min). Thus, the same catheters used for CHD
that are deemed to be malfunctioning despite higher
prescribed Qb (determined by greater arterial and venous
pressure alarms) may not be deemed malfunctioning at the
lower prescribed NHD Qb (fewer arterial and venous alarms)
and may be used for a prolonged period of time. Thus, CHD
catheters not able to obtain a higher Qb would be exchanged
but would otherwise be functional for NHD at a lower Qb.
Lastly, patients on CHD are in-center and increased terminal
event rates may in part reflect a selection bias to in-center
ease of catheter exchange at the earliest suspicion of catheter
dysfunction. In contrast, during NHD, more aggressive
attempts at salvaging a catheter may be employed. For
example, patients with poor flows are often instructed to
flush the catheter on non-dialysis days, and employ more
liberal r-TPA use, a maneuver that would not be practically
feasible in CHD patients.
Limitations in our analysis include our relative short
experience with NHD and small patient numbers, the lack of
data on total hospitalizations in NHD patients, and the lack
of information regarding systemic anticoagulation. In addi-
tion, it was not possible to use a contemporary comparison
cohort (such as self-care CHD patients), given that the
handling of CVC in the self-care center may be carried out by
dialysis nurses. However, our study is strengthened by the
exclusion of confounding catheters used during CHD in
determining complications and by our large prospective
cohort. Extrapolating the morbidity and mortality associated
with CVC use in CHD patients to NHD patients may be
inappropriate. For example, the dialysis prescription achiev-
able in NHD via a CVC far exceeds that of the CHD
population, and this may attenuate the effect of increased
access recirculation and decreased dialysis dose delivery
traditionally associated with CVC.
Conclusion
This study has demonstrated that the incidence and
prevalence of CVC use in our NHD population is 35 and
Kidney International (2006) 70, 1348–1354 1351
J Perl et al.: Central venous catheter outcomes o r i g i n a l a r t i c l e
25%, respectively, and that catheters used for NHD appear to
have similar complication rates as CHD catheters with
increased survival and less adverse terminal event rates.
Although use of a permanent access is preferable, fears over
increased complications of CVC initial use should not deter
the use of NHD as a treatment modality. However, as NHD
continues to evolve as a novel form of renal replacement
therapy, further and ongoing study is needed in NHD
patients to better define the morbidity and mortality of not
only CVC but of all vascular access-related complications.
MATERIALS AND METHODS
This is an observational cohort study with prospectively collected
data. It was approved by the research and ethics board at the
University Health Network.
Study population
Subjects included patients who either converted from CHD to NHD
or whose initial dialysis modality was NHD at the University Health
Network Home HD Program. All 58 NHD patients currently
enrolled in the UHN NHD program and used a CVC at anytime
either during NHD, the NHD training period, or during prior CHD
were eligible for inclusion into the study. Patients included were
initiated on NHD between 1 November 1993 and 31 May 2005.
Patient demographic information such as age, sex, ethnicity, etiology
of end-stage renal disease, and comorbid conditions was prospec-
tively collected into a computerized clinical database. CVC data
collected included anatomic location, dates of insertion and
removal, and reason for removal. Information regarding r-TPA
administration, catheter-associated bacteremia, exit and tunneled
infections, and any access-related hospitalizations was also pro-
spectively collected into the database. All information obtained was
cross-referenced and validated with electronic and paper charts as
well as with direct patient interview when necessary. Catheters were
then categorized as (1) CVC used exclusively during CHD, (2) CVC
used that encompassed the NHD training period, and (3) CVC used
exclusively during NHD.
CVC description and dialysis prescription
CVC access used at the UHN–TGH HD program during the study
period included Uldall–Cook Catheter (Cook Canada Inc.) HIGH-
FLOW Dialysis Catheter (CardioMed Supplies Inc., Gormley, ON,
Canada), Opti-flow/HemoGlide dual-lumen permanent dialysis
catheter (Bard Access Systems, Salt Lake City, UT, USA), and Vaxcel
Plus Chronic Dialysis Catheter (Boston Scientific, Natick, MA,
USA). All CVCs were tunneled, cuffed, and inserted by UHN–TGH
interventional radiologists. Location of the CVC was left to the
discretion of the radiologist performing the procedure. All CVCs
inserted were used in the analysis of outcomes including those with
primary failure (defined as having never been used for an HD
treatment). Catheter care techniques including dressing types, the
use of topical antimicrobials at the catheter exit site, and choice of
locking agent were the same in both NHD and CHD CVC. Any
changes implemented in catheter care techniques were instituted
simultaneously for both NHD and CHD CVC.
NHD treatments consisted of HD at home for 6–8 h, 5–6 nights/
week. Blood flow rates of 100–300 ml/min and F80 polysulfone
dialyzers (Fresenius Medical care, Lexington, MA, USA) or Polyflux
(polyamide) dialyzers (Gambro Inc., Hechingen, Germany) were
used. A dialysate flow rate of 350 ml/min was used during NHD.
During CHD treatments and NHD training, each patient received
HD for 4 h, three times per week. Blood flow rate was prescribed as
400 ml/min and maximized at the nurses’ discretion with dialysate
flow rate of 500–750 ml/min. The same dialyzers were used for NHD
and CHD treatments.
CVC function was assessed during CHD by HD nursing staff
during each CHD treatment and evaluated by the HD physician
when needed. Upon conversion to NHD, CVC function was
monitored during the initial NHD training period that lasted
approximately 6 weeks in the home dialysis unit and included a
subsequent home visit by dialysis nursing staff upon discharge from
training and annually thereafter. Once established in the NHD
program, CVC surveillance was performed when patients expressed
concerns regarding CVC dysfunction and at regular 3-month
intervals during home dialysis clinic visits. Patients were evaluated
and managed by both HD nursing staff and the HD physician. The
NHD caregiver team comprised three nephrologists, one nephrology
trainee, four nurses, one vascular access coordinator, and interven-
tional radiology personnel.
Outcomes
The primary objective was to determine the incident and prevalent
rates of CVC use in the NHD population. Secondary outcomes were
to compare complication rates and catheter cumulative survival
among the CVC used by patients during CHD and after conversion
to NHD. Complication outcomes studied included the development
of a CVC-related infection,39 the need for catheter-directed
thrombolysis, vascular access-related hospitalization, and adverse
terminal CVC events. In the NHD training period, patients may
have used a CVC during CHD and continued it during the
transition to NHD. These catheters were excluded in the analysis of
all secondary outcomes, but were included in the determination of
CVC incidence and prevalence in the NHD population.
r-TPA or Cathflo (Hoffman-La Roche, Ontario, Canada) was
used at a dose of 2 mg suspended in 2 ml of normal saline per
catheter lumen for presumed intraluminal thrombosis and adminis-
tered in accordance with the UHN–TGH medical directive and
protocol (in adherence with current clinical practice guidelines39).
Before r-TPA administration, conservative measures including
patient repositioning, saline flushes and aspiration, and line reversal
were performed by HD nursing staff (in accordance with
UHN–TGH HD medical directive and protocol) to exclude non-
thrombus or mechanical causes of ‘poor flow’. ‘Poor flow’ was
defined as blood flow less than 250 ml/min accompanied by high
venous or arterial access pressures (calibrated identically during
NHD and CHD treatments). Owing to practical considerations,
patients did not routinely undergo radiological investigations to
confirm the presence of intraluminal thrombus before r-TPA use. If
initial r-TPA administration failed to completely restore catheter
patency, further attempts with r-TPA dwells was left to the discretion
of the ordering physician. All outcomes, including the number of
attempts made to clear the catheter, were reported to the vascular
access coordinator and entered into the database. Patients taking
systemic anticoagulation for the purpose of maintaining catheter
patency on CHD were left on anticoagulation for the training and
NHD periods.
Suspected cases of infection were identified by trained HD nurses
who would notify the attending physician. Definitions of CVC
infections were in accordance with Canadian Communicable
Diseases Reporting definitions of catheter-related infections40 and
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were categorized into three groups: (1) exit site infection, (2) tunnel
infection, and (3) bacteremia. Each group was further determined to
be ‘definite,’ ‘probable,’ or ‘suspected’. Cases meeting criteria for
either definite or probable infections were classified as infections.
Vascular access-related hospitalizations were defined as those for
which the primary reason for admission to hospital and/or the
majority of the hospital admission could be attributed as a direct
result of a CVC-related complication. Emergency room, ambulatory
outpatient care visits, and admissions owing to other vascular
access-related complications that necessitated the emergent inser-
tion of a CVC were not included.
Terminal CVC events were divided into two groups, adverse and
non-adverse. Adverse events were defined as terminal catheter events
that necessitated removal of the CVC and included the following:
infection, inadequate flow after failed r-TPA administration and/or
from uncorrectable mechanical problems such as malposition,
dislodging or loosening of the catheter cuff, and cracked or
damaged ports. The decision to remove a CVC based on infection
was left to the discretion of the attending nephrologist in accordance
with clinical practice guidelines and opinion from our vascular
access infection control team.
A non-adverse terminal CVC event was defined as a planned
catheter removal owing to the presence of a functioning permanent
vascular access. Similarly, ongoing use of the catheter beyond the
termination of the study period was labeled as a non-adverse
terminal event; non-adverse events were censored.
Catheter survival was defined as the period of time from the day
of catheter insertion to the day of catheter removal. Owing to the
prospective nature of the clinical database, the outcomes of patients
and their catheters were all known at the end of the study period.
Patients who received a kidney transplant, transferred to another
dialysis center, switched to a different dialysis modality, or died were
censored at that time.
Statistical analysis
In the initial analysis of CVC incidence and prevalence, all access
types used for NHD training and NHD proper were included. All
subsequent analysis of CVC outcomes was limited to patients who
had received a CVC either before or after conversion to NHD. This
excluded patients in the NHD training period where CVC use
overlapped between CHD and NHD periods. All continuous data
were compared using a Student’s t-test, whereas dichotomous data
were compared by w2 analysis. Rate-specific outcomes (event/1000
CVCD) were compared using the exact binomial test for Poisson
distributions (appropriate for rates using person-time denomina-
tors). Time-to-event distributions were estimated using the
Kaplan–Meier method, and compared using the log-rank test. All
tests of significance were two-sided with a P-value o0.05. The
statistical software used was SAS (version 8.2) (SAS Institute Inc.,
Cary, NC, USA).
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